Aptus Pharma Ltd
Our Company is engaged in the business of marketing, and distribution of finished pharmaceutical formulations. While the Company does not own any manufacturing facilities, it operates through a contract manufacturing model. We do not own any manufacturing plants but has entered into contract manufacturing agreement with seven manufacturing units. under various arrangements. Of these, we have formal loan and license agreements in place with two manufacturing units. The remaining production is carried out through informal arrangements with Other Manufacturers, based on purchase orders (PO). We provide a diverse range of pharmaceutical products catering to various therapeutic categories including anti-infectives, gastrointestinal, antacids, anti-allergic and respiratory, nutritional supplements, pain management, neuro-psychiatric, cardiovascular, anti-diabetic, lipid-lowering, and general wellness products. These are offered across a variety of dosage forms, such as tablets, capsules, softgels, syrups, suspensions, injections, ointments, creams, balms, drops, lotions, vials, powders, gels, and sachets.
Timeline
Subscription
Reports
Offer Details
Terms
Application Sizes
Managers & Registrar
Ownership & Proceeds
Shareholding
Objects of the Issue
- Capital Expenditure for Office Premises with furniture and Industrial Racks
- Working Capital
- General corporate purposes
Financials
Profit & Loss
| Financial Year | FY23 | FY24 | FY25 | FY26 | Latest |
|---|---|---|---|---|---|
| RevenueCr | 14 | 18 | 25 | 47 | 81 |
| Operating ProfitCr | 1 | 2 | 5 | 7 | 12 |
| OPM% | 4.5 | 8.7 | 19.7 | 16.0 | 15.3 |
| PBTCr | 0 | 1 | 4 | 6 | 11 |
| PATCr | 0 | 1 | 3 | 5 | 8 |
| EPS | 1 | 5 | 6 | 3 | 5 |
Balance Sheet
| Financial Year | FY23 | FY24 | FY25 | FY26 | Latest |
|---|---|---|---|---|---|
| Equity CapitalCr | 0 | 0 | 5 | 7 | - |
| ReservesCr | 1 | 1 | 2 | 16 | - |
| BorrowingsCr | 2 | 5 | 10 | 7 | - |
| Total AssetsCr | 6 | 10 | 22 | 44 | - |
Cash Flow
| Financial Year | FY23 | FY24 | FY25 | FY26 | Latest |
|---|---|---|---|---|---|
| Operating Cash FlowCr | 0 | -2 | -2 | -6 | - |
| Investing Cash FlowCr | 0 | 0 | -1 | -6 | - |
| Financing Cash FlowCr | 1 | 3 | 7 | 8 | - |
| Net Cash FlowCr | 0 | 0 | 4 | -4 | - |
Strengths & Risks
- Diversified Product Portfolio.
- Robust and Responsive Distribution Network.
- Strategic Manufacturing Partnerships.
- Commitment to High-Quality Standards.
- Competitive and Cost-Effective Pricing.
- Skilled and Committed Human Resources.
- Hybrid Model for Growth.
- Dynamic Marketing Approach.
- Strategic Product Selection.
- Two-Sword Theory.
- Collaboration and Operational Efficiency.
- Human Resources Excellence.
- The company does not have its own manufacturing facility for pharmaceutical products and the company have to relies on third parties for contract manufacturing of the products sold by the Company.
- The company is required to obtain, renew or maintain certain material statutory and regulatory permits and approvals required to operate its business, and if the company fail to does so in a timely manner or at all, its may be unable to operate the company business and its results of operations may be adversely affected.
- The company derives a significant part of the company revenue from few customers. If one or more of such customers choose not to source their requirements from the company or to terminate its contracts or purchase orders, the company business, cash flows, financial condition and results of operations may be adversely affected.
- If the company are unable to protect its intellectual property rights, the company business, results of operations and financial condition may be adversely affected. Further, if its products were found to be infringing on the intellectual property rights of a third-party, the company could be required to cease selling the infringing products, causing the company to lose future sales revenue from such products and face substantial liabilities for infringement of intellectual property rights.
- The Company may be exposed to product liability and other claims arising from defective medicines manufactured by third-party Contract Manufacturers, despite having manufacturing agreements in place, as indemnity terms are not pre-determined.
- The company are highly dependent on the medical practitioners including general physicians, paediatricians, gynaecologists, cardiologists, endocrinologists, neurologists, and others. Any disruption in such understanding may adversely impact its business operations.